Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Biggest Award Yet, But Strategy Remains Unclear

 
• By Andrew McConaghie
Novavax
Novavax's recombinant protein nanoparticle vaccine offers an alternative approach to Moderna and AstraZeneca

More from Business

More from Scrip